Australia will eliminate its Pharmaceutical Benefits Pricing Authority effective April 1 as part of a plan to streamline its drug-approval process. The independent authority makes recommendations on prices for new drugs and vaccines listed with the government's Pharmaceutical Benefits Scheme and national immunization program. The Department of Health said the change is a "key component" in reducing the time it takes to get new drugs listed and improve access to medicines.

Full Story:
PharmaTimes (U.K.)

Related Summaries